AstraZeneca buys into Harvard’s stem cell tech for diabetes R&D – FierceBiotech
BioPharma-Reporter.com |
AstraZeneca buys into Harvard's stem cell tech for diabetes R&D
FierceBiotech Harvard professor Doug Melton is having quite a week. His work on potential cell therapies for diabetes just fueled the launch of a well-funded biotech startup, and now he's signed up with AstraZeneca ($AZN) to help the drugmaker spotlight new … AstraZeneca to Collaborate with the Harvard Stem Cell Institute in Diabetes AstraZeneca and Harvard Team Up on Stem Cell Therapies for Diabetes AstraZeneca Inks Collaboration With Harvard Stem Cell Institute |
